ECSP13013043A - Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma - Google Patents

Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma

Info

Publication number
ECSP13013043A
ECSP13013043A ECSP13013043A ECSP13013043A EC SP13013043 A ECSP13013043 A EC SP13013043A EC SP13013043 A ECSP13013043 A EC SP13013043A EC SP13013043 A ECSP13013043 A EC SP13013043A
Authority
EC
Ecuador
Prior art keywords
divalproex sodium
prepare
liquid composition
same
oral liquid
Prior art date
Application number
Other languages
English (en)
Inventor
Dipak Sahana
Prasad Patil
Ganesh Narayan Phadtare
Manish Grover
Shripad Jathar
Original Assignee
Abbott Healthcare Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46939730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13013043(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Healthcare Pvt Ltd filed Critical Abbott Healthcare Pvt Ltd
Publication of ECSP13013043A publication Critical patent/ECSP13013043A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige a una composición oral, líquida de sabor agradable, que comprende sodio de divalproex, y a un proceso para preparar la misma. Particularmente, la presente invención se refiere a una composición oral, líquida, estable, tal como una solución que comprende sodio de divalproex y a un proceso para preparar la misma.
ECSP13013043 2011-05-02 2013-11-25 Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma ECSP13013043A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1365MU2011 2011-05-02

Publications (1)

Publication Number Publication Date
ECSP13013043A true ECSP13013043A (es) 2014-01-31

Family

ID=46939730

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13013043 ECSP13013043A (es) 2011-05-02 2013-11-25 Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma

Country Status (6)

Country Link
BR (1) BR112013027685A2 (es)
CL (1) CL2013003137A1 (es)
CO (1) CO6801771A2 (es)
EC (1) ECSP13013043A (es)
MX (1) MX2013012827A (es)
WO (1) WO2012150607A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104248627A (zh) * 2013-06-25 2014-12-31 北大方正集团有限公司 丙戊酸半钠泡腾干混悬剂及其制备方法
BE1026024B1 (nl) * 2018-02-16 2019-09-16 Neogen Nv Werkwijze voor het bereiden van een oplossing omvattende valproïnezuur en/of een of meerdere van zijn zouten, genoemde oplossing en gebruik
CN114760976A (zh) 2019-12-16 2022-07-15 高露洁-棕榄公司 含有菊粉的口腔护理组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
FR2643556B1 (fr) 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
US6528090B2 (en) 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US6419953B1 (en) 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
US6511678B2 (en) 1998-12-18 2003-01-28 Abbott Laboratories Controlled release formulation of divalproex sodium
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
US20070082046A1 (en) * 2005-10-11 2007-04-12 Banner Pharmacaps, Inc. Enteric valproic acid
US20110015267A1 (en) * 2009-07-20 2011-01-20 Deanna Jean Nelson Methods for the preparation and use of aqueous solutions of magnesium valproate hydrate and l-carnitine

Also Published As

Publication number Publication date
CL2013003137A1 (es) 2014-08-01
BR112013027685A2 (pt) 2016-12-27
WO2012150607A2 (en) 2012-11-08
CO6801771A2 (es) 2013-11-29
WO2012150607A3 (en) 2013-02-14
MX2013012827A (es) 2014-02-11

Similar Documents

Publication Publication Date Title
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
IN2015KN00262A (es)
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
MX353706B (es) Anticuerpos contra csf-1r humano y usos de los mismos.
CL2016001150A1 (es) Formas sólidas de ácido [(5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]aético, composiciones, y usos de las mismas.
UY33735A (es) Compuestos antivirales
MX2019003738A (es) Compuestos antivirales.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
EA201391488A1 (ru) Композиции со сниженной вязкостью
IN2014MN00859A (es)
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
EA029539B8 (ru) Фармацевтическая композиция ситаглиптина
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
EA201592227A1 (ru) Стабильные растворы объединенных активных фармацевтических ингредиентов для перорального применения
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
BR112012032248A2 (pt) composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
MX2015009617A (es) Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
CO6321288A2 (es) Sales de compuestos inhibidores de vih
ECSP13013043A (es) Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma
IN2015DN04074A (es)
IN2014DN10658A (es)
IN2014DN03245A (es)
MX358995B (es) Forma amorfa estabilizada de agomelatina, un proceso para su preparación y composiciones farmacéuticas que la contienen.